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Structural biology continues to benefit from an expanding toolkit, which is
helping to gain unprecedented insight into the assembly and organization of
multi-protein machineries, enzyme mechanisms and ligand/inhibitor binding.
The combination of results from X-ray free-electron lasers (XFELs), modern
synchrotron crystallographic beamlines and cryo-electron microscopy (cryoEM)
is proving to be particularly powerful. The highly brilliant undulator beamlines at
modern synchrotron facilities have empowered the crystallographic revolution
of high-throughput structure determination at high resolution. The brilliance of
the X-rays at these crystallographic beamlines has enabled this to be achieved
using microcrystals, but at the expense of an increased absorbed X-ray dose and
a consequent vulnerability to radiation-induced changes. The advent of serial
femtosecond crystallography (SFX) with X-ray free-electron lasers provides a
new opportunity in which damage-free structures can be obtained from much
smaller crystals (2 mm) and more complex macromolecules, including membrane
proteins and multi-protein complexes. For redox enzymes, SFX provides a
unique opportunity by providing damage-free structures at both cryogenic and
ambient temperatures. The promise of being able to visualize macromolecular
structures and complexes at high resolution without the need for crystals using
X-rays has remained a dream, but recent technological advancements in
cryoEM have made this come true and hardly a month goes by when the
structure of a new/novel macromolecular assembly is not revealed. The
uniqueness of cryoEM in providing structural information for multi-protein
complexes, particularly membrane proteins, has been demonstrated by examples
such as respirasomes. The synergistic use of cryoEM and crystallography in lead-
compound optimization is highlighted by the example of the visualization of
antimalarial compounds in cytochrome bc1. In this short review, using some
recent examples including our own work, we share the excitement of these
powerful structural biology methods.
1. Introduction
The ability to visualize atomic details in three dimensions has
proven transformative in the way that we think of biological
machines and understand the chemistry that is performed in
a complex, coordinated manner at, for example, the catalytic
core of an enzyme or protein complex such as photosystem II.
Until recently, X-ray crystallography and nuclear magnetic
resonance (NMR) spectroscopy have been the main players.
NMR does not require protein molecules to be coaxed into
crystals, but carries a limitation on the size of the molecule for
which a structure can be determined. The tremendous success
of X-ray crystallography over the last 30 years has largely been
owing to (i) the availability of increasingly brighter synchro-
tron X-ray sources, (ii) the ability to screen crystallization
conditions using robotics and in situ visualization platforms,
(iii) the use of highly optimized beamlines with efficient single-
photon-counting detectors, (iv) automation, (v) optimized
user-friendly data-acquisition systems and (vi) sophisticated
data-processing/analysis packages. The drive towards ever-
increasing brightness of X-ray sources has led to diffraction-
limited synchrotron-radiation (SR) sources (Eriksson et al.,
2014; MAX-IV in Sweden and SIRIUS in Brazil) and the
establishment of X-ray free-electron laser (XFEL) facilities
in the USA, Japan, Germany, Switzerland and South Korea.
XFELs provide huge gains in peak intensity, allowing high-
resolution molecular structures to be obtained from crystals of
a few nanometres in size. They enable the structure determi-
nation of complex systems both at room temperature and at
cryogenic temperature without any radiation damage, as the
X-ray pulses are shorter than the vibrational/rotational
frequencies. In a way, these are ‘time-frozen’ structures and
provide a true representation of the molecule prior to any
effect from X-ray-induced photochemistry. Despite the
success of crystallography, a serious bottleneck remains,
namely the ability to obtain diffracting crystals. This is parti-
cularly the case for membrane proteins, large multi-protein
complexes and encounter complexes, which by definition are
transient in nature, but are crucial for understanding biolo-
gical function. In the context of cryoEM, the revolution that
we are witnessing was aptly described as the ‘method of the
decade’ at a micro-symposium at the 24th IUCr Congress in
August 2017 (Hasnain, 2016). CryoEM has already provided
high-resolution (<2 A˚) structures of multi-protein complexes
with structural details comparable to those of crystal struc-
tures. In 2017 alone, the number of structures determined by
this method exceeded the number that had been determined
prior to 2014. This was the year when crystallography marked
the 100th anniversary of its first Nobel prize through the
United Nations’ declaration of 2014 as the International Year
of Crystallography.
There are currently 148 037 structures (as of 17th January
2019) in the Protein Data Bank (PDB), with 90% being
determined by X-ray crystallography, of which 82% were
obtained using synchrotron beamlines. Fig. 1 provides a
detailed breakdown of structures determined by X-ray crys-
tallography, NMR and EM. The pace of change for cryoEM
came at the turn of the century, when 11 structures were
deposited in 2000. We now have 2800
deposited structures that were deter-
mined by cryoEM. For NMR, structure
deposition peaked in 2007, and it is
currently producing400 structures per
annum. It is proving to be a powerful
approach to study inherently disordered
proteins and for rapidly screening frag-
ment libraries. X-ray crystallography
still dominates the field, and has now
reached ten thousand structures per
annum. Despite the wealth of structures
in the Protein Data Bank, a closer
examination reveals that 89% of the
structures, i.e. 126 994, are of proteins or
complexes with a molecular weight of
less than 160 kDa. Furthermore, only
4% of the deposited structures have a molecular weight in
excess of 300 kDa. This deficiency is largely owing to the
limitations of obtaining high-quality protein and the unpre-
dictability of obtaining diffraction-quality crystals. Given that
cryoEM comes into its own for proteins with molecular
weights in excess of 120 kDa, one may expect this structural
gap to be overcome in the coming decade.
2. Damage-free structures using X-rays: a unique place
for XFELs
The highly intense microfocus crystallographic beamlines
equipped with efficient photon-counting detectors at modern
synchrotrons have increased the quality and the number of
structures that can be obtained. Much smaller crystals (20–
50 mm) can be used for high-resolution crystallographic data
collection. However, this has come at the cost of an increased
absorbed X-ray dose and consequent radiation-induced
changes that can occur during data collection (Hough et al.,
2008). Neutron crystallography has for decades remained the
only radiation-damage-free structural probe, but the advent of
femtosecond XFEL crystallography provides a new opportu-
nity. Owing to the time structure of the pulse, damage-free
structures can be obtained using XFELs from much smaller
crystals and from more complex macromolecules, including
membrane proteins and multi-protein complexes, as illu-
strated by the following examples.
2.1. Photosystem II
Photosynthesis is central to aerobic life and utilizes the
CaMn4O5 centre of photosystem II (PSII) to split water and
generate molecular oxygen through the four-step Kok cycle,
harnessing the redox properties of manganese (Kok et al.,
1970). The definition of this catalytic centre and how it cycles
through the Kok cycle to produce molecular oxygen has been
a major goal in the field for over 30 years. The first crystal
structure of PSII determined by SR crystallography appeared
at the turn of the century at 3.8 A˚ resolution (Zouni et al.,
2001). This was improved to 1.9 A˚ resolution in 2011 using
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Figure 1
The numbers of structures deposited in the Protein Data Bank (PDB; Berman et al., 2000) in a
particular year associated with the X-ray crystallography (lilac), NMR (salmon) and cryoEM (blue)
methods. Note that the data for 2019 are only to 17th January.
improved synchrotron beamlines, detectors and crystals
(Umena et al., 2011). Although these structures provided
detailed insight into the organization of this 350 kDa multi-
subunit complex, questions remained about the integrity of
the CaMn4O5 centre in the dark stable state (S1) of PSII owing
to X-ray-induced structural changes (Yano et al., 2005, 2006).
Shen and coworkers addressed this by femtosecond XFEL
crystallography using the serial femtosecond rotational crys-
tallography (SF-ROX) approach with cryogenically main-
tained large crystals of PSII (1.0  0.4  0.15 mm). By using
more than a hundred such crystals, they were able to establish
a damage-free structure of PSII at 1.95 A˚ resolution (Suga et
al., 2015). Most of the Mn–Mn distances were found to be
shortened by 0.1–0.3 A˚ compared with the structure obtained
using SR X-rays, with slight changes in the Mn–O and Mn–
ligand distances. As in the SR structure, one of the oxygens,
O5, of CaMn4O5 was found to be unusually distant from the
nearby manganese ions, suggesting that O5 may participate
in O O bond formation. Using time-resolved serial femto-
second crystallography (Suga et al., 2017), the structural
changes in PSII induced by two-flash illumination at room
temperature have been defined, establishing the changes that
occur between the S1 and S3 states. These heroic experiments
provided structures to 2.35 A˚ resolution at room tempera-
ture and used over two million crystals of 20 mm in size. A
water molecule located 3.5 A˚ from the Mn4CaO5 cluster
disappeared from the map upon two-flash illumination,
reducing the distance between another water molecule and
the O4 atom and indicating a proton-transfer event. This was
accompanied by the appearance of a positive peak around O5:
a unique 4-oxo bridge located in the quasi-centre of Mn1 and
Mn4 (Fig. 2). This suggested the insertion of a new O atom
(O6) close to O5, providing an O O distance of 1.5 A˚
between these two O atoms consistent with the formation of
an O O bond.
2.2. Copper nitrite reductase in denitrification
Copper nitrite reductases (CuNiRs) perform the first
committed step of denitrification (NO2
 + e + 2H+ $ NO +
H2O) and have been extensively studied over the last 25 years
using SR crystallography. CuNiR was the first copper protein
for which a structure was determined at atomic resolution
(Ellis et al., 2003), i.e. with a resolution of better than 1.2 A˚,
the resolution at which carbon–carbon bonds can be resolved.
Denitrification is not only important from a bioenergetics
perspective, but it is also crucial in terrestrial and oceanic
nitrogen cycling and makes a significantly increasing contri-
bution to global warming by the release of N2O, an ozone-
depleting and greenhouse gas that is some 300-fold more
potent than CO2.
CuNiRs utilize two types of copper, T1Cu and T2Cu, where
T1Cu receives an electron from a cognate partner while
catalysis occurs at T2Cu through a displacement mechanism.
The substrate replaces a water molecule before being
converted to nitric oxide through well controlled and regu-
lated proton and electron transfer. The two copper redox
centres are linked together by a Cys130–His129 bridge, which
is a novel feature of these enzymes, in which two redox centres
are linked via neighbouring residues to form the catalytic
cores. The T1Cu centres in these novel catalytic cores are
prone to conversion to a reduced state by X-rays during a
typical X-ray crystallographic data collection (Hough et al.,
2008). The T2Cu site of the resting-state enzyme, in contrast,
remains unaffected at much higher X-ray doses. When the
substrate nitrite is bound at T2Cu, it converts quickly to NO
during X-ray data collection, indicating that electron transfer
from T1Cu to T2Cu is regulated and occurs efficiently when
substrate nitrite is present for catalysis. These features have
been exploited to obtain a large number of structures from
one crystal and to build up a structural movie capturing the
conversion of nitrite to nitric oxide and its subsequent return
to the resting state. This serial crystallography approach,
termed multiple structures from one crystal (MSOX; Horrell
et al., 2016), has been made possible only recently by micro-
focus beams and efficient photon-counting detectors, mini-
mizing the X-ray dose to a level enabling the determination of
several structures from the same sample volume. This X-ray
radiolysis approach to drive a chemical reaction is thus, in
principle, applicable to all redox catalysts (Schlichting et al.,
2000). It is clear from the above discussion that it is most likely
that none of the structures of CuNiRs collected at powerful
synchrotron beamlines represent a ‘damage-free’ structure.
SFX and SF-ROX XFEL crystallography have been used to
study a number of CuNiRs [NiRs from Alcaligenes faecalis
(AfNiR; Fukuda, Tse, Nakane et al., 2016), Geobacillus ther-
modenitrificans (GtNiR; Fukuda, Tse, Suzuki et al., 2016) and
Alcaligenes xylosoxidans (AxNiR; Halsted et al., 2018)] to
obtain damage-free structures of the resting state as well as a
topical reviews
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Figure 2
The catalytic centre of the native XFEL-determined structure of
photosystem II (two-flash data set; PDB entry 5gti) showing details of
the CaMn4O5 cluster and the surrounding residues assigned at 2.35 A˚
resolution. Coordination bonds are shown in red and hydrogen bonds in
black; residues are colour-coded according to the chain identifier.
Manganese ions are shown as lilac spheres, the calcium ion as a green
sphere, and waters and O atoms as small red spheres.
number of catalytically important forms. In the case ofAxNiR,
the resting state ofAxNiR obtained by SF-ROX using 64 large
(1 0.8 0.05 mm) blue crystals unexpectedly revealed an O2
ligand bound to the T2Cu in a brand-new binding mode for a
diatomic ligand in CuNiRs (Fig. 3). The observation of O2 in a
time-frozen structure of the as-isolated oxidized enzyme
provided long-awaited evidence for the mode of O2 binding in
CuNiRs. This provided insights into how this CuNiR functions
as an oxidase, reducing O2 to H2O2, or as a superoxide
dismutase (SOD), since it was shown to have significant
dismutase activity 20 years ago (Strange et al., 1999). We note
that a number of CuNiRs have been observed to function as
oxidases, reducing O2 to H2O2, or even as superoxide dismu-
tases (SODs), but this remains a relatively unexplored aspect
of CuNiR catalysis.
2.3. Rhodopsins
Rhodopsin is a G-protein-coupled receptor and is a light-
driven proton pump that is central to vision by the human eye
in dim light. Using very low dose EM, Henderson and Unwin
determined the first (7 A˚ resolution) structure of bacterio-
rhodopsin more than 40 years ago, showing the detailed
arrangement of seven transmembrane -helices (Henderson
& Unwin, 1975). This work proved that integral membrane
proteins have a tertiary folding with the same secondary-
structure elements as water-soluble proteins. In the 1990s,
Henderson and coworkers succeeded in obtaining the first
atomic structure of bacteriorhodopsin to 3.5 A˚ resolution
using electron diffraction from two-dimensional crystals
(Henderson et al., 1990; Subramaniam et al., 1993). Synchro-
tron X-ray crystallography provided the structure to a reso-
lution of 2.5 A˚ in 1997 using the microfocus beamline at the
ESRF, which was the best beamline at the time to handle 20 
20  5 mm crystals (Pebay-Peyroula et al., 1997). The higher
resolution improved the loop conformations and a number of
side-chain residues. It also helped to identify eight water
molecules constituting the proton-translocation pathway in
the ground state. The first crystal structure of a mammalian
rhodopsin, bovine rhodopsin, was obtained at 2.8 A˚ resolution
at the turn of the century by the MAD method using data
collected at SPring-8 (Palczewski et al., 2000). Although close
similarity was found to the structures of bacterial rhodopsin,
the arrangement of the seven helices was found to be different,
with larger and more organized extra-membrane regions than
those in bacteriorhodopsins. During the last three years,
damage-free structures of human rhodopsin and bacterio-
rhodopsin have been determined using XFEL crystallography
at SACLA and LCLS. In an attempt to define the structural
changes that accompany the photocycle of bacteriorhodopsin
proposed over half a century ago, a pump–probe approach has
been used to construct a structural movie at 2 A˚ resolution,
maintaining the microcrystals at 20C. Nearly two million
crystals were used in each of two independent studies: one
carried out at SACLAusing a nanosecond pump laser and the
other at LCLS using a femtosecond pump laser (Nango et al.,
2016; Nogly et al., 2018). In the SACLA experiment, a set of 13
time delays between the pump laser pulse and the XFEL pulse
were chosen to build a structural movie: t = 16 ns, 40 ns,
110 ns, 290 ns, 760 ns, 2 ms, 5.25 ms, 13.8 ms, 36.2 ms, 95.2 ms,
250 ms, 657 ms and 1.725 ms. The SACLA experiments were
complemented by those at the LCLS, where different sets of
time delays between the pump laser pulse and the XFEL pulse
were chosen (300 fs, 600 fs, 900 fs, 1100 fs and 10 ps) to capture
the isomerization of retinal at 1.5 A˚ resolution. These
experiments showed how excited all-trans retinal samples
different conformational states within the binding pocket of
the protein before passing through a twisted geometry and
emerging in the 13-cis conformation.
3. CryoEM: some recent highlights providing atomic
details of complex structures
The ability of cryoEM to determine structures that have
proven intractable to other methods to sub-4 A˚ resolution has
provided a series of high-profile structures over the last few
years. The transformation of cryoEM into the ‘method of the
decade’ has come from steady progress over the last 20 years
on many technical fronts. These include developments in
direct electron detectors, improved microscope design and
more sophisticated data-processing algorithms (Subramaniam
et al., 2016). Many important cellular processes are governed
by complex protein assemblies. The ribosome, the determi-
nation of the structure and mechanism of assembly of which
by SR X-ray crystallography was recognized by a Nobel prize
in 2009, has long been used in electron-microscopy experi-
ments (Frank & Agrawal, 2000; Lata et al., 1996); indeed,
760 entries in the EMDB relate to the ribosome. Recent
years have seen not only an improvement in the resolution of
these complexes by EM, but also an increase in the diversity of
the systems studied. The recent structures of the spliceosome,
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Figure 3
SF-ROX damage-free structure of nitrite reductase from A. xylosoxidans
reveals a dioxygen species at the catalytic copper site. The OMIT Fo  Fc
electron-density map is contoured at the 5 level around the dioxygen
molecule and is coloured green.
ubiquitination and the respirasome are some examples. Here,
we briefly discuss two cases.
3.1. Respirasome
The development of our structural understanding of the
respiratory chain has been advanced by new cryoEM struc-
tures. For example, new understanding has been reached as to
how the proton gradient is harnessed by ATP synthase to
produce ATP, with a surprising organization of the main
proton-translocation domain (Ku¨hlbrandt & Davies, 2016).
Removing the need for crystallization, which can offer
significant challenges for larger protein complexes, has
permitted the solution of not just large protein complexes in
the respiratory chain such as ATP synthase (Zhou et al., 2015),
cytochrome bc1 (Amporndanai et al., 2018) and complex I
(Agip et al., 2018), but also supercomplexes such as the
1.7 MDa respirasome, which offers insights into the arrange-
ment of respiratory-chain complexes in the mitochondria.
Four respirasome structures have been published to date from
porcine, ovine and bovine sources, all revealing a similar
architecture consisting of a complex I core with a complex III
dimer (cytochrome bc1) packed against the side, with the
complex III dimer packed between the complex I core and
complex IV (Fig. 4; Gu et al., 2016; Wu et al., 2016; Letts et al.,
2016; Sousa et al., 2016). The interaction of complex I and
complex III is facilitated by NDUFA11, which directly inter-
acts with both subunits, acting to bridge the gap between the
two subunits and ensure close packing interactions. Moreover,
it has been shown that three lipids are also involved in this
interaction and may behave like a ‘glue’ to propagate protein–
protein interactions. The supercomplexes form the basis of
new models to understand how electron transfer is coordi-
nated between the subunits. It is interesting to note that higher
molecular-weight species have been detected, and it will be
interesting to see, using developments such as electron
tomography, how complex formation occurs within the bilayer
environment as opposed to detergent-extracted particles. This
is an example where combining high-resolution X-ray struc-
tures of individual components and an 5 A˚ resolution EM
structure of the whole supercomplex machinery could prove
to be a powerful toolset to open new ways of looking at the
biological workings at higher levels.
3.2. Proteins involved in neurodegenerative diseases
Amyloid plaques, fibre formation and the aggregation of
proteins are signatures of a number of neurodegenerative
diseases. It has been shown that these are formed from life-
sustaining abundant proteins that become defective, described
in the field as ‘gain of function’. Our understanding of several
important neurodegenerative diseases has rapidly changed
recently with a series of landmark papers detailing the struc-
ture of tau and amyloid- proteins (Fitzpatrick et al., 2017;
Gremer et al., 2017). These new structures provide unprece-
dented detail into the structural arrangement of this important
clade of proteins. Interestingly, for tau different distinct folds
can be seen in Pick’s disease and Alzheimer’s disease, despite
the same building blocks, with phosphorylation predicted to
play a role (Falcon et al., 2018).
4. Structure-guided drug discovery
Crystallographic structure-based drug development has
yielded several notable drugs during the last 30 years. In the
1990s several drugs emerged from structure-guided approa-
ches, including Trusopt (targeting carbonic anhydrase for
glaucoma), Agenerase, Aluviran and Viracept (AIDS drugs
targeting HIV protease), and Relenza and Tamiflu (influenza
drugs developed using the crystal structure of neuraminidase),
thus establishing crystallographic structural information as an
essential ingredient for most major drug-discovery programs.
Structure-based or structure-guided drug design often occurs
in a cycle, in which new molecules are synthesized, tested and
crystallized with the target protein. The structural analysis
helps to evaluate the binding mode and suggests ways to
modify the molecule to either enhance the binding or prevent
off-target binding. In the last 20 years, fragment-based drug
topical reviews
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Figure 4
Structure of the respirasome determined to 5.4 A˚ resolution by single-particle cryoEM (Gu et al., 2016). The modelled structure is shown as a surface
view (a), fitted within the EM map (b) and as a ribbon diagram (c). The three main components, complex I (CI), complex III (CIII) and complex IV
(CIV), are labelled along with the bilayer (dashed lines).
discovery (Shuker et al., 1996) has made a significant impact as
an approach that is able to cover a large amount of chemical
space, which, when combined with structural information, can
rapidly lead to candidate drug molecules. Notable examples
(Blundell, 2017) of successful fragment-derived drugs are
vemurafenib (which targets a mutant form of BRAF, a kinase,
thus extending life for patients with skin cancer), venetoclax1
(which binds to BCL-2 to treat chronic lymphocytic
leukaemia) and ribociclib, which was developed by Astex and
Novartis to target the protein kinase Cdk4 as a first-line
treatment for advanced breast cancer in combination with
letrozole.
4.1. The role of cryoEM in drug discovery
During the last five years, cryoEM has become a powerful
approach in structure determination, particularly of membrane
proteins or large complexes. Although still limited in resolu-
tion compared with both X-ray crystallography and NMR,
it can provide valuable insights into inhibitor binding. For
example, within the transient receptor potential channel
(TRP) membrane-protein family there had been a paucity of
structural information on the full channels, with most struc-
tural work using the ‘divide-and-conquer’ approach of crys-
tallizing the more amenable soluble domains. However, since
2013, 50 new single-particle cryoEM structures have been
determined from all the major clades (TRPM, TRPA, TRPV
and TRPC; Madej & Ziegler, 2018). A common feature of
these channels has been the presence of bound inhibitors,
which have often been used to stabilize and ‘lock’ the target to
improve the resulting resolution. For TRPV1 not only was the
binding site for the spider toxin identified, but the role of lipids
in facilitating this interaction could also be seen for the first
time by using nanodisc technology (Gao et al., 2016). Another
example is the case of imidazoleglycerolphosphate-dehydratase
(IGPD), an essential enzyme in histidine biosynthesis. The
Arabadopsis homologue was highly amenable to crystal-
lization, resulting in several high-resolution structures (Bisson
et al., 2016). These structures not only revealed the mode of
binding, but also the molecular basis for the nanomolar
equipotency of potent enantiomers. However, the structure of
the yeast isoform, which is more sensitive to small-molecule
inhibitors and intractable to crystallization, has recently been
determined by cryoEM. This revealed stabilization of the
inhibitor-binding loop in the yeast homologue, ‘locking’ the
inhibitor in the pocket, which was predicted to create a higher
sensitivity to triazole-phosphonate inhibitors in the yeast
homologue compared with that from Arabidopsis (Rawson et
al., 2018).
For some medically important systems, a significant hurdle
in structure determination is obtaining sufficient quantities
of material. This can often be a limiting factor, despite the
development of crystallization robotics that can dispense
nanolitre droplets of protein sample. The large amount of
screening space that is required to find a suitable crystal-
lization condition can be a limiting factor. For large protein
complexes this becomes more challenging, and specialized
cellular machinery may be required for the synthesis of
sufficient protein for extraction from host tissue. In contrast,
EM is less demanding on the quantity of sample than a typical
X-ray or NMR experiment. This is highlighted by the structure
of the malarial translocon, which is essential for exporting
effector proteins over the membrane (Ho et al., 2018). The
recent cryoEM structure to 3.5 A˚ resolution will provide new
avenues for structure-based drug-design pipelines. Through
substrate profiling, inhibitors have been designed based on
structural differences between the human and plasmodium
20S proteasome, with the binding of these inhibitors shown by
cryoEM. This impressive study shows the power of cryoEM
when tackling proteins from a native source (Li et al., 2016).
4.2. Antimalarials targeting cytochrome bc1
One example where X-ray crystallography and cryoEM
have been used in a complementary and powerful manner is
for the antimalarial target complex III or cytochrome bc1.
According to data from the World Health Organization, the
infection rate of malaria has declined by 41% since the turn of
the century, but 212 million new cases and 429 000 deaths still
occurred globally in 2015. Targeting the electron-transport
chain (ETC) of plasmodial mitochondria has been shown to be
therapeutically successful. Atovaquone, an inhibitor of the
cytochrome bc1 complex, used in conjunction with proguanil
(the drug combination Malarone) remains in clinical use in its
generic formulation after the expiry of the GSK patent in 2013
after usage for 14 years. Increasing resistance and the expiry of
the patent resulted in extensive research to find alternative
drugs that target the ETC in general and cytochrome bc1 in
particular.
Cytochrome bc1 exists as a heterodimer of two multi-
subunit proteins embedded in the inner mitochondrial
membrane. It facilitates electron transport to cytochrome c via
the Q cycle, in which electrons are utilized at two sites of the
cytochrome b subunit for the oxidation of ubiquinol (at the Qo
site) and the reduction of ubiquinone (at the Qi site) (Fig. 5).
The subunit composition of cytochrome bc1 can vary between
species. Prokaryotic complexes only contain 3–4 subunits,
while mitochondrial proteins contain 10–11 different subunits
(Trumpower, 1990). However, all cytochrome bc1 complexes
have a catalytic core containing three essential subunits:
cytochrome b, cytochrome c1 and the Rieske iron–sulfur
protein. In the absence of the structure of plasmodial cyto-
chrome bc1, the structure of Saccharomyces cerevisiae cyto-
chrome bc1 has been used as a surrogate for that of the parasite,
showing atovaquone in the Qo site (Birth et al., 2014), where
its location is enforced by a polar contact between the O atom
(O3) of the hydroxyl group of the ligand and the His181 side
chain from the Rieske protein (Fig. 6). The inhibitor binding
explained the broad target spectrum, species-specific efficacies
and acquired resistances (Stickles et al., 2015).
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1 According to Drugs to Watch, the forecast sale for venetoclax is 1.477 billion
US$ (http://images.info.science.thomsonreuters.biz/Web/ThomsonReuters
Science/%7B7e677448-1313-40ae-9978-6be1a8532a08%7D_A4_MarketInsight_
Report_0213_012__edits_2.pdf).
Crystallographic studies have been important in suggesting
the development of dual-site inhibition of cytochrome bc1 as a
valuable strategy for antimalarial combination therapy, one of
which is combining atovaquone with ELQ-300 targeting the Qi
site of cytochrome b (Stickles et al., 2015). The discovery of a
connection between the cardiotoxicity of the 4(1H)-pyridone
class of inhibitors, GSK932121 and GW844520, and the ability
of this class to overcome parasite Qo-based atovaquone
resistance has provided new opportunities. These compounds
bind to the Qi site of cytochrome b in bovine cytochrome bc1, a
surrogate of the host (Capper et al., 2015), encouraging the
development of Qi binders [Figs. 6(b), 6(c) and 6(d)] with the
goal of decreasing the cardiotoxicity of the compounds and
developing stronger inhibitors for plasmodial cytochrome bc1.
Crystal structures show that the carbonyl O atoms of the
ligand are within 3.5 A˚ of both Ser35 in loop A and OD1 of
Asp228 in loop E, allowing the formation of possible hydrogen
bonds. All recently structurally identified Qi binders, including
SCR0911 (Amporndanai et al., 2018) [Fig. 6(d)], make similar
potential hydrogen bonds within the Qi site to either His201,
topical reviews
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Figure 6
Qo and Qi sites of cytochrome bc1, with inhibitors bound in the cytochrome b subunit. (a) S. cerevisiae structure with atovaquone bound in the Qo site,
making a hydrogen bond to the His121 side chain from the Rieske iron–sulfur protein. S and Fe atoms are shown as yellow and orange spheres,
respectively (Birth et al., 2014). (b, c, d) Bovine cytochrome bc1 with (b) GSK932121, (c) GW844520 (Capper et al., 2015) and (d) SCR0911 inhibitors
bound in the Qi site (Amporndanai et al., 2018). Residues and inhibitors are shown as sticks. Selected possible hydrogen bonds are illustrated by black
dashed lines.
Figure 5
The plasmodial mitochondrial electron-transport chain.
Ser35 or Asp228 independently or a combination of these
residues. It has been shown that small changes in the 4(1H)-
quinolone scaffold can change the binding site from Qi to Qo,
which makes it crucial that these are visualized directly in
experimentally determined structures. An alternative approach
for proving the exact binding site is to test the drug action
against a Plasmodium falciparum strain containing the Qi site
mutation I122L in cytochrome b. However, a significant
limitation of the crystallographic approach is the requirement
for significant quantities of protein, with concentrations of
50 mg ml1 being required for crystallization. This reliance
on protein and an inability to overexpress it limits studies of
the malarial homologue itself. Therefore, a cryoEM approach,
although limited in resolution, could provide a link by being
suitable for the study of systems in which protein is more
limiting. As a proof of principle, the structure of the bovine
cytochrome bc1 complex was recently determined by single-
particle cryoEM to 4.0 A˚ resolution with bound inhibitors
(Fig. 7), which were clearly identified within the Qi site
(Amporndanai et al., 2018). This opens up the potential for
using a similar approach to study the plasmodial cytochrome
bc1 and other complexes of the mitochondrial ETC for both
enzyme-mechanism studies and structure-guided development
of antimalarial drugs. Moreover, recent cryoEM studies have
now revealed the structure of cytochrome bc1 from Flavo-
bacterium johnsoniae, showing a unique arrangement of the
complex (Sun et al., 2018).
5. Ease of access, data quality and appraisal of
structures from cryoEM and X-ray crystallography
A significant limiting factor in the cryoEM field with respect to
structure determination is the availability of high-end instru-
mentation which is open to ‘non-expert’ users. The high capital
cost of the microscopes and the continued operating and
maintenance cost with appropriate technical staff is a signifi-
cant undertaking for a university-based group. Despite this,
new facilities are being built across the UK and internationally
which have opened their doors to ‘non-expert’ users, thus
contributing to the expansion of the community. In addition,
national facilities are emerging, some of which are co-located
with synchrotron facilities, for example eBIC at the Diamond
Light Source (Saibil et al., 2015). The success of these is reliant
upon sufficient training and the availability of lower specifi-
cation microscopes for screening at the institutional/regional
level that are well supported. Furthermore, the determination
of new EM structures requires typical data-collection times of
the order of days for single-particle EM projects, compared
with minutes for X-ray crystallographic data. Screening of
samples is also more challenging in cryoEM. Even with ‘on-
the-fly’ data processing, a sufficient amount of data must be
collected before one can obtain a good estimation of factors
such as homogeneity, orientation distribution and particle
number per micrograph, which all play a role in the final
resolution. In contrast, screening crystals can be much more
rapid. A single test image, even at the home source, gives a
good approximation of the final resolution at a synchrotron,
albeit with radiation damage and anisotropy during data
collection sometimes limiting the final resolution.
Although typical in crystallization experiments, the screening
of conditions such as pH and salt concentration is often poorly
defined in EM. The ability to quickly screen hundreds of
crystals in a few hours from distinctly different conditions
allows a broad chemical space to be quickly explored. This is
not true for cryoEM experiments, where the ‘final resolution’
of a structure is only obtained after extensive image proces-
sing. Despite technological improvements in grid making, the
quality of grids and sample uniformity remain a significant
limiting factor. The automation of crystallographic facilities
allows the selection of a well diffracting crystal for high-
resolution data collection which
can be processed ‘on-the-fly’, and
in favourable cases the structure
can be solved before the end of
the session. In the case of
SFX-based crystallography, two
approaches for obtaining crystal-
lographic data have emerged.
One relies on a sample-injection
system that requires small (2–
20 mm) well diffracting crystals,
while the other is a fixed-target
rotational crystallographic (SF-
ROX) approach that requires
larger (>300 mm) crystals. Both
of these approaches provide
‘damage-free’ structures owing to
the intrinsic properties of the
X-ray laser pulse, which is shorter
in duration (10 fs) than atomic
movement. The main limitations
that remain are the availability of
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Figure 7
The Qi site of bovine cytochrome bc1 in a cryoEM map with antimalarial compounds (Amporndanai et al.,
2018). (a) The Qi site with GSK932121 density (coloured green) suggests there are two modes of inhibitor
binding accompanied by rotation around the oxygen–carbon bond. The binding pose shown in green agrees
with the crystal structure, with the trifluoromethyl group pointing towards Met194. There is additional
density which suggests that the trifluoromethoxyphenyl group could be rotated and point towards Asp228,
revealing an additional mode of binding (shown in blue). (b) The Qi site with the inhibitor SCR0911 (shown
in pink) located in strong density. A possible hydrogen bond from the inhibitor to His201 is shown as
dashed line and is clearly defined in EM density. For all maps, the density is contoured at 3.
XFEL beamtime and the preparation of suitable samples
and their delivery to the XFEL beams. Both EM and XFEL
experiments are data-intensive and thus require large data-
processing/storage capabilities.
There is also significant work to be performed in the vali-
dation of EM-determined structures. At worst, the use of high-
resolution search models can significantly bias the end result
(Henderson, 2013), and as with any modest resolution struc-
ture care must be taken when interpreting the resulting
density (Neumann et al., 2018). At the typical resolution of
current cryoEM maps it can still be difficult to unambiguously
assign small-molecule density and side chains. Robust vali-
dation software developed by the X-ray crystallographic
community for analysing the resulting structural geometry
(Ramachandran plot, clashscores, density-fit analysis) is
available and it is important that this is routinely used when
reporting EM structures. The lack of a conventional ‘R factor’
removes a useful metric for the quality of the model fit to the
data. However, with the availability of phase information the
maps generated by single-particle EM are not influenced by
the refined structure, removing the ‘phase bias’ that may exist
in some crystal structures. As in all structural biology, the key
is in rigorous assessment of the data and making sure that the
conclusions drawn are consistent with the resolution obtained.
Moreover, showing both the map and model in the published
structure rather than only the refined model allows the reader
to make their own assessment of the strength of the conclu-
sions drawn. This is even more important in the case of small-
molecule binding, where in the reported structure the corre-
sponding density may be absent or only be shown for the
bound inhibitor and not the surrounding residues, making it
difficult to assess the noise level within the binding site.
6. Concluding remarks
The above case studies have demonstrated that the richness
of structural biology can best be harnessed by combining
methods where practical and possible. It is wonderful that
structures can be obtained without crystallizing the biological
system by using single-particle imaging by cryoEM, which
indeed is proving to be the ‘method of the decade’. Structural
details that are only available at atomic resolution (when
atoms making C—C bonds are clearly resolved) are often
the underpinning aspects of the chemistry that defines the
mechanism of an enzyme or processes such as electron
transfer, bond formation and breakage. Resolving structures
at such atomic resolutions is going to continue to require well
diffracting crystals, powerful synchrotrons and efficient
detectors for the foreseeable future. The challenge for
synchrotron-based crystallography is to minimize X-ray-
induced damage, particularly when radiolysis can cause
chemical changes. XFEL-based crystallography, by virtue of
the nature of the source (femtosecond pulses), will continue to
offer the unprecedented advantage of ‘damage-free’ struc-
tures at high resolutions at both ambient and cryogenic
temperatures. It also offers the unique capability for time-
resolved studies either via pump–probe experiments (Suga et
al., 2017; Nogly et al., 2018) or by combining SFX with mix-
and-inject systems (Stagno et al., 2017). The impact of cryoEM
will continue to expand and will remain critical in providing
structural details of large macromolecular complexes. It is not
inconceivable that the atomic details of the whole mitochon-
drial electron-transport chains of a number of important
parasites will be resolved by cryoEM within the next five
years. In the coming years, we can expect extensive efforts to
be devoted to the rigorous validation of cryoEM structures,
automatic building/refinement of models and opening of the
method to the wider biological community, in a manner similar
to X-ray crystallography. Further exciting developments are
being seen in the field of MicroED (electron diffraction). The
structure of lysozyme showed the power of this technique for
studying protein structures, and recent work by the Gonen
group has shown this to be a powerful approach for deter-
mining structures from very small crystals (Shi et al., 2016).
Two separate reports of the model system apoferritin solved
to 1.6 A˚ resolution by single-particle cryoEM show the
potential for gaining ‘high’ resolution EM data, although less
robust systems will certainly require further development to
reach such resolutions.
It is our view that the strength of structural biology going
forward is likely to be in the combination of techniques, rather
than in a sole technique expanding and dominating the field.
Even with recent developments in EM, sub-65 kDa molecular
masses remain a limiting factor, with the poor signal to noise in
the raw images making particle identification and alignment
a significant challenge. In crystallography, multi-protein
complexes, particularly those which involve membrane
proteins or where the complexes are not stable over the
crystallization time scale, will remain a limitation. The serial
crystallography approach developed at XFELs is likely to be
implemented at the more powerful synchrotrons, many of
which will undergo major upgrades in the next eight years. The
new beamlines and detector technology, with remote data
collections and robotic crystal mounting, offer significant gains
in the speed and ease of synchrotron data collection. On-the-
fly data processing allows the data quality to be quickly
assessed and ensures that full high-quality data sets are
collected.
Structural biology is commonly an ‘averaging’ technique, be
that in the need for a homogeneous crystal with multiple
repeating units or the requirement for tens of thousands of
particles that must be averaged to improve the signal to noise
in EM. One limitation of this approach is that it can lead to
one or only a handful of states being determined, often those
that dominate in the ground state. Capturing the structural
changes that occur during catalysis or transport is a significant
challenge, not least owing to the time scales of the events.
However, recent years have seen a growing development of
time-resolved methodologies. Landmark studies have shown
that XFEL sources can provide femtosecond-to-millisecond
information on biological processes, including catalysis
(Johansson et al., 2017; Stagno et al., 2017). For larger
conformational changes in the microsecond-to-millisecond
time frame, time-resolved cryoEM can synergize with other
topical reviews
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methods such as SAXS, but can additionally provide atomic-
level information (Frank, 2017). It should be noted that rapid
developments in the field of mass spectrometry may provide
an excellent partner for traditional structural techniques, and
using fast photochemical oxidation of proteins (FPOP)-based
approaches one can map structural changes in a time-depen-
dent manner (Li et al., 2018). Moreover, mass spectrometry
can sort conformational heterogeneities and ‘soft-land’ these
onto EM grids to overcome problems of sample heterogeneity.
Although still some way from its full potential, it highlights the
bright future in combining techniques (Benesch et al., 2010).
Thus, the expanding toolkit of structural biology, with
further advances in the technologies associated with cryoEM,
synchrotron radiation and XFEL crystallography and their
ease of use, will continue to enable the wider community to
address more complicated and demanding scientific questions,
thus ensuring the pole position of structural biology.
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